共 122 条
[1]
Durie BG(1975)A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer 36 842-854
[2]
Salmon SE(2005)International staging system for multiple myeloma J Clin Oncol 23 3412-3420
[3]
Greipp PR(2015)Revised international staging system for multiple myeloma: a report from international myeloma working group J Clin Oncol 33 2863-2869
[4]
San Miguel J(2015)Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma Blood Cancer J 5 e363-3084
[5]
Durie BG(2015)Frontline therapy of multiple myeloma Blood 125 3076-101
[6]
Palumbo A(2014)Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy Cancer Cell 25 91-1086
[7]
Avet-Loiseau H(2012)Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma Blood 120 1077-2616
[8]
Oliva S(2018)Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups Leukemia 32 2604-1194
[9]
Vu T(2015)Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential Leukemia 29 1186-1060
[10]
Gonsalves W(2011)Multiple myeloma N Engl J Med 364 1046-548